Identifying breast cancer patients at risk of relapse despite pathological complete response after neoadjuvant therapy

被引：23

作者：

Huober, Jens ^{[1
,2
]}

van Mackelenbergh, Marion ^{[3
]}

Schneeweiss, Andreas ^{[4
]}

Seither, Fenja ^{[5
]}

Blohmer, Jens-Uwe ^{[6
,7
]}

Denkert, Carsten ^{[8
]}

Tesch, Hans ^{[9
]}

Hanusch, Claus ^{[10
]}

Salat, Christoph ^{[11
]}

Rhiem, Kerstin ^{[12
]}

Solbach, Christine ^{[13
]}

Fasching, Peter A. ^{[14
]}

Jackisch, Christian ^{[15
]}

Reinisch, Mattea ^{[16
]}

Lederer, Bianca ^{[5
]}

Mehta, Keyur ^{[5
]}

Link, Theresa ^{[17
]}

Nekljudova, Valentina ^{[5
]}

Loibl, Sibylle ^{[5
]}

Untch, Michael ^{[18
]}

机构：

[1] Univ Frauenklin Ulm, Brustzentrum, Ulm, Germany

[2] Kantonsspital St Gallen, Brustzentrum, Dept Interdisziplinare Med Dienste, St Gallen, Switzerland

[3] Univ Klinikum Schleswig Holstein, Brustzentrum, Campus Kiel,Arnold Heller Str 3, D-24105 Kiel, Germany

[4] Natl Ctr Tumorerkrankungen, Heidelberg, Germany

[5] German Breast Grp, Neu Isenburg, Germany

[6] Charite Univ Med Berlin, Gynakol, Berlin, Germany

[7] Charite Univ Med Berlin, Brustzentrum, Berlin, Germany

[8] Philipps Univ Marburg, Inst Pathol, Marburg, Germany

[9] Ctr Hamatol & Onkol Bethanien Frankfurt, Frankfurt, Germany

[10] Klinikum Roten Kreuz Munchen, Munich, Germany

[11] Hamatol Onkol Schwerpunktpraxis Salat Stotzer, Munich, Germany

[12] Uniklin Koln, Zentrum Familiarer Brust & Eierstockkrebs, Cologne, Germany

[13] Univ Klinikum Frankfurt, Frankfurt, Germany

[14] Univ Klinikum Erlangen, Erlangen, Germany

[15] Sana Klinikum Offenbach, Offenbach, Germany

[16] Evang Kliniken Essen Mitte, Essen, Germany

[17] Tech Univ Dresden, Dept Gynecol & Obstet, Dresden, Germany

[18] HELIOS Klinikum Berlin Buch, Berlin, Germany

来源：

NPJ BREAST CANCER | 2023年 / 9卷 / 01期

关键词：

TAXANE-BASED CHEMOTHERAPY; STAGING SYSTEM; CAPECITABINE; BEVACIZUMAB; SURVIVAL; GEPARQUINTO; OUTCOMES; TRASTUZUMAB; CARBOPLATIN; EVEROLIMUS;

D O I：

10.1038/s41523-023-00525-2

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

This retrospective pooled analysis aims to identify factors predicting relapse despite a pathologic complete response (pCR) in patients with breast cancer (BC). 2066 patients with a pCR from five neoadjuvant GBG/AGO-B trials fulfill the inclusion criteria of this analysis. Primary endpoint is disease-free survival (DFS); secondary endpoints is distant DFS (DDFS) and overall survival (OS). After a median follow-up of 57.6 months, DFS is significantly worse for patients with positive lymph nodes (cN+ vs cN0 hazard ratio [HR] 1.94, 95%CI 1.48-2.54; p < 0.001). In patients with triple-negative tumors, lobular histology (lobular vs other HR 3.55, 95%CI 1.53-8.23; p = 0.003), and clinical nodal involvement (cN+ vs cN0 HR 2.45, 95%CI 1.59-3.79; p < 0.001) predict a higher risk of DFS events. Patients with HER2-positive cT3/4 tumors have a significantly higher risk of relapse (cT3/4 vs cT1 HR 2.07, 95%CI 1.06-4.03; p = 0.033). Initial tumor load and histological type predict relapse in patients with a pCR.

引用

页数：12

共 39 条

[1] Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials [J].

Alberro, J. A. ;

Ballester, B. ;

Deulofeu, P. ;

Fabregas, R. ;

Fraile, M. ;

Gubern, J. M. ;

Janer, J. ;

Moral, A. ;

de Pablo, J. L. ;

Penalva, G. ;

Puig, P. ;

Ramos, M. ;

Rojo, R. ;

Santesteban, P. ;

Serra, C. ;

Sola, M. ;

Solarnau, L. ;

Solsona, J. ;

Veloso, E. ;

Vidal, S. ;

Abe, O. ;

Abe, R. ;

Enomoto, K. ;

Kikuchi, K. ;

Koyama, H. ;

Masuda, H. ;

Nomura, Y. ;

Ohashi, Y. ;

Sakai, K. ;

Sugimachi, K. ;

Toi, M. ;

Tominaga, T. ;

Uchino, J. ;

Yoshida, M. ;

Coles, C. E. ;

Haybittle, J. L. ;

Moebus, V. ;

Leonard, C. F. ;

Calais, G. ;

Garaud, P. ;

Collett, V. ;

Davies, C. ;

Delmestri, A. ;

Sayer, J. ;

Harvey, V. J. ;

Holdaway, I. M. ;

Kay, R. G. ;

Mason, B. H. ;

Forbe, J. F. ;

Franci, P. A. .

LANCET ONCOLOGY, 2018, 19 (01) :27-39

[2] Circulating Tumor Cells in Breast Cancer Patients Treated by Neoadjuvant Chemotherapy: A Meta-analysis [J].

Bidard, Francois-Clement ;

Michiels, Stefan ;

Riethdorf, Sabine ;

Mueller, Volkmar ;

Esserman, Laura J. ;

Lucci, Anthony ;

Naume, Bjorn ;

Horiguchi, Jun ;

Gisbert-Criado, Rafael ;

Sleijfer, Stefan ;

Toi, Masakazu ;

Garcia-Saenz, Jose A. ;

Hartkopf, Andreas ;

Generali, Daniele ;

Rothe, Francoise ;

Smerage, Jeffrey ;

Muinelo-Romay, Laura ;

Stebbing, Justin ;

Viens, Patrice ;

Magbanua, Mark Jesus M. ;

Hall, Carolyn S. ;

Engebraaten, Olav ;

Takata, Daisuke ;

Vidal-Martinez, Jose ;

Onstenk, Wendy ;

Fujisawa, Noriyoshi ;

Diaz-Rubio, Eduardo ;

Taran, Florin-Andrei ;

Cappelletti, Maria Rosa ;

Ignatiadis, Michail ;

Proudhon, Charlotte ;

Wolf, Denise M. ;

Bauldry, Jessica B. ;

Borgen, Elin ;

Nagaoka, Rin ;

Caranana, Vicente ;

Kraan, Jaco ;

Maestro, Marisa ;

Brucker, Sara Yvonne ;

Weber, Karsten ;

Reyal, Fabien ;

Amara, Dominic ;

Karhade, Mandar G. ;

Mathiesen, Randi R. ;

Tokiniwa, Hideaki ;

Llombart-Cussac, Antonio ;

Meddis, Alessandra ;

Blanche, Paul ;

d'Hollander, Koenraad ;

Cottu, Paul .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2018, 110 (06) :560-567

[3] Association of Pathologic Complete Response to Neoadjuvant Therapy in HER2-Positive Breast Cancer With Long-Term Outcomes A Meta-Analysis [J].

Broglio, Kristine R. ;

Quintana, Melanie ;

Foster, Margaret ;

Olinger, Melissa ;

McGlothlin, Anna ;

Berry, Scott M. ;

Boileau, Jean-Francois ;

Brezden-Masley, Christine ;

Chia, Stephen ;

Dent, Susan ;

Gelmon, Karen ;

Paterson, Alexander ;

Rayson, Daniel ;

Berry, Donald A. .

JAMA ONCOLOGY, 2016, 2 (06) :751-760

[4] Gene signatures in patients with early breast cancer and relapse despite pathologic complete response [J].

Bruzas, Simona ;

Gluz, Oleg ;

Harbeck, Nadia ;

Schmid, Peter ;

Cortes, Javier ;

Blohmer, Jens ;

Seiberling, Christine ;

Chiari, Ouafaa ;

Harrach, Hakima ;

Ataseven, Beyhan ;

Shenoy, Satyendra ;

Dyson, Mark H. ;

Traut, Eugen ;

Theuerkauf, Ingo ;

Gebauer, Daniel ;

Kuemmel, Sherko ;

Reinisch, Mattea .

NPJ BREAST CANCER, 2022, 8 (01)

[5] Nomogram for accurate prediction of breast and axillary pathologic response after neoadjuvant chemotherapy in node positive patients with breast cancer [J].

Choi, Hee Jun ;

Ryu, Jai Min ;

Kim, Isaac ;

Nam, Seok Jin ;

Kim, Seok Won ;

Yu, Jonghan ;

Lee, Jeong Eon ;

Lee, Se Kyung .

ANNALS OF SURGICAL TREATMENT AND RESEARCH, 2019, 96 (04) :169-176

[6] ERBB2 mutation frequency in lobular breast cancer with pleomorphic histology or high-risk characteristics by molecular expression profiling [J].

Christgen, Matthias ;

Bartels, Stephan ;

Radner, Martin ;

Raap, Mieke ;

Rieger, Luisa ;

Christgen, Henriette ;

Gluz, Oleg ;

Nitz, Ulrike ;

Harbeck, Nadia ;

Lehmann, Ulrich ;

Kreipe, Hans .

GENES CHROMOSOMES & CANCER, 2019, 58 (03) :175-185

[7] Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis [J].

Cortazar, Patricia ;

Zhang, Lijun ;

Untch, Michael ;

Mehta, Keyur ;

Costantino, Joseph P. ;

Wolmark, Norman ;

Bonnefoi, Herve ;

Cameron, David ;

Gianni, Luca ;

Valagussa, Pinuccia ;

Swain, Sandra M. ;

Prowell, Tatiana ;

Loibl, Sibylle ;

Wickerham, D. Lawrence ;

Bogaerts, Jan ;

Baselga, Jose ;

Perou, Charles ;

Blumenthal, Gideon ;

Blohmer, Jens ;

Mamounas, Eleftherios P. ;

Bergh, Jonas ;

Semiglazov, Vladimir ;

Justice, Robert ;

Eidtmann, Holger ;

Paik, Soonmyung ;

Piccart, Martine ;

Sridhara, Rajeshwari ;

Fasching, Peter A. ;

Slaets, Leen ;

Tang, Shenghui ;

Gerber, Bernd ;

Geyer, Charles E., Jr. ;

Pazdur, Richard ;

Ditsch, Nina ;

Rastogi, Priya ;

Eiermann, Wolfgang ;

von Minckwitz, Gunter .

LANCET, 2014, 384 (9938) :164-172

[8] The Clinical Significance of Breast-only and Node-only Pathologic Complete Response (pCR) After Neoadjuvant Chemotherapy (NACT) A Review of 20,000 Breast Cancer Patients in the National Cancer Data Base (NCDB) [J].

Fayanju, Oluwadamilola M. ;

Ren, Yi ;

Thomas, Samantha M. ;

Greenup, Rachel A. ;

Plichta, Jennifer K. ;

Rosenberger, Laura H. ;

Tamirisa, Nina ;

Force, Jeremy ;

Boughey, Judy C. ;

Hyslop, Terry ;

Hwang, Shelley .

ANNALS OF SURGERY, 2018, 268 (04) :591-601

[9] Neoadjuvant bevacizumab and anthracycline-taxane-based chemotherapy in 678 triple-negative primary breast cancers; results from the geparquinto study (GBG 44) [J].

Gerber, B. ;

Loibl, S. ;

Eidtmann, H. ;

Rezai, M. ;

Fasching, P. A. ;

Tesch, H. ;

Eggemann, H. ;

Schrader, I. ;

Kittel, K. ;

Hanusch, C. ;

Kreienberg, R. ;

Solbach, C. ;

Jackisch, C. ;

Kunz, G. ;

Blohmer, J. U. ;

Huober, J. ;

Hauschild, M. ;

Nekljudova, V. ;

Untch, M. ;

von Minckwitz, G. .

ANNALS OF ONCOLOGY, 2013, 24 (12) :2978-2984

[10] Clinical tumor stage is the most important predictor of pathological complete response rate after neoadjuvant chemotherapy in breast cancer patients [J].

Goorts, Briete ;

van Nijnatten, Thiemo J. A. ;

de Munck, Linda ;

Moossdorff, Martine ;

Heuts, Esther M. ;

de Boer, Maaike ;

Lobbes, Marc B. I. ;

Smidt, Marjolein L. .

BREAST CANCER RESEARCH AND TREATMENT, 2017, 163 (01) :83-91

← 1 2 3 4 →